Glaxo Group Limited

Glaxo S.p.a.

Convergence Pharmaceuticals Limited

Janssen Biopharma, Inc.

The General Hospital Corporation

Glaxosmithkline LLC

Alios Biopharma, Inc.

Glaxo Wellcome Spa

Pliva D.d.

Escape Bio, Inc.

Aptuit (verona) Srl, an Evotec Company

Glaxosmithkline Intellectual Property Development Limited

Nerre Therapeutics Limited

Benevolentai Bio Limited

Daniele Andreotti

Stefano Biondi

Carmela Napolitano

Leonid Beigelman

Guangyi Wang

Haiying He

Giovanni Gaviraghi

Anh P Truong

Alcide Perboni

Tino Rossi

Anh Truong

Simon Edward Ward

Sergio Lociuro

Daniele Donati

Simone Spada

Andrew John Eatherton

Bruno Tamburini

Karamjit Singh Jandu

Oliver James Philps

Riccardo Giovannini

Giuseppe Alvaro

Fabrizio Micheli

Romano Di Fabio

Jacob Bradley Schwarz

Agostino Marasco

Paul Bamborough

Dieter Hamprecht

Sandro Belvedere

Albert W Garofalo

Qian Liu

Gorjana Lazarevski

Luca Tarsi

David Norton

Stéphane De Lombaert

Kevin Thewlis

Laurence G Rahme

Giovanna Tedesco

Markus Bergauer

Karin Ann Stein

Antun Hutinec

Roberto Profeta

Alessandro Falchi

Giorgio Pentassuglia

Anna Checchia

Jessica Tibasco

Miljenko Dumic

Stjepan Mutak

Drazen Pavlovic

Luca Arista

Federica Damiani

Zorica Marusic-Istuk

Aldo Feriani

Claudio Bismara

Domenica Antonia Pizzi

Fabio Maria Sabbatini

Xuedong Dai

Francesca Cardullo

Emiliangelo Ratti

Francois Lepine

Claudia Beato

Ilaria Bientinesi

Gabriella Finizia

Roberto Carlesso

Vlado Stimac

Alfredo Paio

Suleman Alihodzic

Andrea Berdik

Marko Djerek

Natasa Marsić

Elena Serra

Silvia Bernardi

Marco Migliore

Federica Budassi

John Alexander Winders

Damien Maura

Stefano Fontana

Michele Negri

Antonio Felici

Helen Susanne Price

Paula Louise Nichols

Manuela Ciraco

Vesna Erakovic

Anna Quaglia

Wolfgang Schoenfeld

David Sheppard

The present application provides malonamide compounds, and derivatives thereof (e.g., N-aryl malonamides (NAM), acetamides, oxalamides, and the like), that are useful, for example, for the treatment of acute, chronic/persistent, and/or relapsing infections. Pharmaceutical compositions, methods of treating diseases (e.g., bacterial infections), and methods of reducing bacterial virulence are also provided.

Broad spectrum antivirulence, anti-persistence compounds

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Indazoles and azaindazoles as LRRK2 inhibitors

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Antiviral compounds

Compounds for the treatment of paramyxovirus viral infections

Compounds for the treatment of paramoxyvirus viral infections

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease.

2-(benzyloxy) benzamides as LRRK2 kinase inhibitors

The invention relates to novel piperazine compounds of formula (I): to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.

Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

Compounds

Compounds of formula (I) wherein the variables are defined herein, pharmaceutical compositions thereof and methods for treatment using the same. 

The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein

3-triazolylthiaalkyl-3-azabicyclo (3-1-O) hexanes and their use as dopamine D3 receptor ligands

This invention relates to potentiation of the glutamate receptor by novel compounds of formula (I):  The invention also relates to the use of the derivatives in treating diseases and conditions mediated by potentiation of the glutamate receptor, compositions containing the derivatives and processes for their preparation.

Compounds which potentiate glutamate receptor and uses thereof in medicine

The present invention relates to 14 or 15 membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body 

Macrolides

11,12 &#x3b3; lactone ketolides of the following formula:and pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, and Rare as described herein. The disclosure also relates to processes for the preparation of such compounds, to compositions containing them, and to their use in the therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

Macrolide antibiotics

A compound of formula (I), salts and metabolically labile esters thereof, wherein R represents optionally substituted aryl or heteroaryl group; A represents a propylene chain or A is a chain of members one of which is selected from an oxygen or sulphur atom or the group NH or a substituted derivative thereof and the other two members are methylene groups, having antibacterial activity, processes for their preparation and to their use in medicine.

Tricyclic carbapenem compounds

Urea derivatives for use in treating bacterial infections

Growing community of inventors

Verona, Italy

Daniele Andreotti